Plasma high-density lipoprotein cholesterol but not apolipoprotein A-I is a good correlate of the visceral obesity-insulin resistance dyslipidemic syndrome

被引:18
作者
Couillard, C
Lamarche, B
Tchernof, A
Prudhomme, D
Tremblay, A
Bouchard, C
Moorjani, S
Nadeau, A
Lupien, PJ
Despres, JP
机构
[1] CHUL,DIABET RES UNIT,RES CTR,ST FOY,PQ,CANADA
[2] UNIV LAVAL,PHYS ACT SCI LAB,ST FOY,PQ G1K 7P4,CANADA
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 1996年 / 45卷 / 07期
基金
英国医学研究理事会;
关键词
D O I
10.1016/S0026-0495(96)90164-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Apolipoprotein (apo) A-I is a major component of high-density lipoproteins (HDLs), and it has been suggested that measurement of apo A-I may provide additional information in the assessment of coronary heart disease (CHD) risk. In the present study in a sample of 111 men (age [mean +/- SD], 35.3 +/- 6.6 years), we determined whether a low apo A-I concentration is associated with the cluster of metabolic abnormalities that characterize the visceral obesity-insulin resistance dyslipidemic syndrome. For this purpose, the first and fourth quartiles of apo A-I and HDL cholesterol (HDL-C) concentrations were compared in relation to body fat distribution, glucose tolerance, and plasma insulin and lipoprotein levels. Men in the first quartile (< the 25th percentile) of HDL-C, as compared with men in the fourth quartile (> the 75th percentile), were characterized by an elevated visceral adipose tissue (AT) accumulation (P < .05), as well as by increased plasma levels of triglycerides ([TGs] P < .0001), apo B (P < .0005), and insulin (P < .01). These differences were not found when the first and fourth quartiles of plasma apo A-I concentrations were compared. These results suggest that plasma levels of HDL-C are more closely associated with the various features of the visceral obesity-insulin resistance syndrome than plasma apo A-I. Copyright (C) 1996 by W.B. Saunders Company
引用
收藏
页码:882 / 888
页数:7
相关论文
共 48 条
[1]   BODY-FAT DISTRIBUTION, PLASMA-LIPIDS, AND LIPOPROTEINS [J].
ANDERSON, AJ ;
SOBOCINSKI, KA ;
FREEDMAN, DS ;
BARBORIAK, JJ ;
RIMM, AA ;
GRUCHOW, HW .
ARTERIOSCLEROSIS, 1988, 8 (01) :88-94
[2]  
AVOGARO P, 1979, LANCET, V1, P901
[3]  
BEHNKE AR, 1974, EVALUATION REGULATIO, P20
[4]  
BITTOLO BG, 1984, ATHEROSCLEROSIS, V53, P69
[5]   HAZARDS IN SUBGROUPS OF HUMAN OBESITY [J].
BJORNTORP, P .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1984, 14 (04) :239-241
[6]   DECREASED HDL2 AND HDL3 CHOLESTEROL, APO A-I AND APO A-II, AND INCREASED RISK OF MYOCARDIAL-INFARCTION [J].
BURING, JE ;
OCONNOR, GT ;
GOLDHABER, SZ ;
ROSNER, B ;
HERBERT, PN ;
BLUM, CB ;
BRESLOW, JL ;
HENNEKENS, CH .
CIRCULATION, 1992, 85 (01) :22-29
[7]   SUR UN DOSAGE RAPIDE DU CHOLESTEROL LIE AUX ALPHA-LIPOPROTEINES ET AUX BETA-LIPOPROTEINES DU SERUM [J].
BURSTEIN, M ;
SAMAILLE, J .
CLINICA CHIMICA ACTA, 1960, 5 (04) :609-609
[8]  
CREMER P, 1988, KLIN WOCHENSCHR, V66, P42
[9]   DISCRIMINATIVE VALUE OF LIPIDS AND APOPROTEINS IN CORONARY HEART-DISEASE [J].
DEBACKER, G ;
ROSSENEU, M ;
DESLYPERE, JP .
ATHEROSCLEROSIS, 1982, 42 (2-3) :197-203
[10]   USE OF POLYETHYLENE GLYCOL TO SEPARATE FREE AND ANTIBODY-BOUND PEPTIDE HORMONES IN RADIOIMMUNOASSAYS [J].
DESBUQUOIS, B ;
AURBACH, GD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1971, 33 (05) :732-+